Sinclair Andrew

SEC CIK: 0001762451

SEC filings (opens in a new tab)

No open-market purchases or sales filed in the past year.

Current role at each company

ACET Adicet Bio, Inc.Directoras of Jun 23, 2026
SLNO Soleno Therapeutics IncDirectoras of May 18, 2026
SRRA Sierra Oncology, Inc.Directoras of Jul 1, 2022
VRNA Verona Pharma plcDirectoras of Aug 10, 2021

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 0; With open-market trades

Trades

Every Form 4 that lists Sinclair Andrew as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

SLNO Soleno Therapeutics Inc

Director2 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Mar 31, 2022 (view filing)	Mar 29	2 days	Sinclair AndrewDirector	PPurchase	+7.72M	–	–	+74.9%18.0M after
Mar 31, 2022 (view filing)	Mar 29	2 days	Sinclair AndrewDirector	PPurchase	+7.72M	–	–	–7.72M after	Derivative

SRRA Sierra Oncology, Inc.

Director1 trade

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Feb 1, 2022 (view filing)	Jan 31	1 day	Sinclair AndrewDirector	PPurchaseCommon Stock, $0.001 par value	+150.0K	$27.00	+$4.05M	+12.9%1.31M after	Duplicate filing

ACET Adicet Bio, Inc.